(Alliance News) - PureTech Health PLC said founded entity Akili Inc will start trading on the Nasdaq Capital Market on Monday, after raising funds which will go towards video-game based treatment for children. Read More
(Alliance News) - PureTech Health PLC on Tuesday announced it received USD115.4 million after selling a portion of its stake in Karuna Therapeutics Inc. Read More
(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears. Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023. Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Begins late-stage clinical study of its wholly-owned candidate LYT-100, or deupirfenidone, in idiopathic pulmonary fibrosis. Will evaluate efficacy of two doses, as well as relative tolerability and efficacy with pirfenidone. IPF is a chronic condition causing progressive scarring of the lungs, which currently has a poor prognosis. Also advances LYT-200 programme through clinical development, and plans to begin leukemia study by the end of 2022. Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Announces that its founded firm Entity Vedanta Biosciences Inc launches a new manufacturing facility. The facility will "provide clinical and commercial supply of oral therapies" for people infected with a diarrhoea-causing bacteria, firm says. Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Investee Gelesis Holdings Inc receives another USD15 million pre-order for its weight management aid product Plenity from its distribution partner, New-York based telehealth firm Ro. It brings the total orders from Ro to USD55 million, out of which USD45 million was ordered in the last 12 months, PureTech Health adds. Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Announces results from phase two study of LYT-100-COV on patients with post acute or long Covid with respiratory complications. Read More
(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, June 20 after completing its quarterly review. Read More
(Alliance News) - British Gas-owner Centrica PLC and chemical firm Johnson Matthey PLC are set to return to the FTSE 100 index next month, replacing television broadcaster ITV PLC and postal operator Royal Mail PLC, according to indicative changes released by FTSE Russell on Tuesday. Read More
(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point. Read More
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Approves share buyback of up to USD50 million. Programme follows "follows consultation with shareholders and is consistent with PureTech's capital allocation strategy and stated approach to drive additional value for its shareholders," company says. PureTech says it had USD413.2 million of net cash and cash equivalents at March 31. Given size of balance sheet, PureTech is confident it can return capital to shareholders and also maintain "sufficient cash on hand to deliver" on strategic priorities. Read More
(Alliance News) - Boston-based biotechnology company PureTech Health PLC's founded entity Gelesis Holdings Inc said on Wednesday that its weight loss drug showed positive responses in adults in clinical trials. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More